Zoetis Inc. (NYSE:ZTS) Shares Sold by Wedbush Securities Inc.
Wedbush Securities Inc. reduced its position in Zoetis Inc. (NYSE:ZTS) by 0.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,443 shares of the company’s stock after selling 26 shares during the period. Wedbush Securities Inc.’s holdings in Zoetis were worth $589,000 as of its most recent filing with the SEC.
A number of other institutional investors have also recently modified their holdings of ZTS. Assetmark Inc. raised its position in shares of Zoetis by 4.6% in the first quarter. Assetmark Inc. now owns 1,918 shares of the company’s stock worth $102,000 after buying an additional 85 shares during the period. Guardian Life Insurance Co. of America raised its position in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares during the period. Point72 Asia Hong Kong Ltd purchased a new position in shares of Zoetis during the first quarter worth about $111,000. Advisory Services Network LLC purchased a new position in shares of Zoetis during the first quarter worth about $112,000. Finally, First Interstate Bank raised its position in shares of Zoetis by 3.5% in the first quarter. First Interstate Bank now owns 2,250 shares of the company’s stock worth $120,000 after buying an additional 76 shares during the period. Institutional investors own 92.70% of the company’s stock.
Zoetis Inc. (ZTS) opened at 60.74 on Tuesday. Zoetis Inc. has a 52 week low of $46.86 and a 52 week high of $63.85. The stock has a market cap of $29.71 billion, a price-to-earnings ratio of 34.34 and a beta of 1.02. The company has a 50 day moving average price of $62.14 and a 200 day moving average price of $58.11.
Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.53. The firm had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. The firm’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.49 earnings per share. Analysts expect that Zoetis Inc. will post $2.34 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Zoetis Inc. (NYSE:ZTS) Shares Sold by Wedbush Securities Inc.” was first posted by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright law. The correct version of this report can be read at https://www.watchlistnews.com/zoetis-inc-nysezts-shares-sold-by-wedbush-securities-inc/1489871.html.
ZTS has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $67.00 target price for the company in a research note on Wednesday, May 10th. Jefferies Group LLC raised their target price on Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. BMO Capital Markets restated a “buy” rating and issued a $60.00 target price on shares of Zoetis in a research note on Thursday, May 4th. Argus restated a “buy” rating and issued a $69.00 target price (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, CL King initiated coverage on Zoetis in a research note on Friday, May 26th. They issued a “buy” rating and a $71.00 target price for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Zoetis has a consensus rating of “Buy” and an average target price of $64.78.
Zoetis Company Profile
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.